Abstract: Objective The aim of this study was to investigate the clinical efficacy of ultrafiltration, concentration and reinfusion of ascites (UCRA) and alprostadil and terlipressin combination in treatment of patients with cirrhosis complicated by refractory ascites (RA). Methods 104 patients with cirrhosis complicated with RA were recruited in the Department of Infectious Diseases in our hospital between March 2017 and June 2018, and were randomly divided into two groups, with 52 in each, receiving UCRA and synthetical treatment, e.g. combination of UCRA and intravenous administration of alprostadil and terlipressin. All patients were followed-up for six months. Results At the end of one week treatment, the velocity of main portal vein and velocity of splenic vein in synthetical treatment group were (25.6±1.5)cm/s and (27.3±2.7)cm/s, significantly rapider than 【(21.4±1.3)cm/s and (25.4±2.1)cm/s, respectively, P<0.05】 in patients receiving UCRA treatment alone; serum nitric oxide (NO), endothelin-1 (ET-1) and endotoxin were (13.4±2.1)μmol/L, (53.2±10.3)pg/mL and (31.4±13.2)pg/mL,significantly different as compared to 【(16.2±2.3)μmol/L, (68.3±12.6)pg/mL and (49.5±14.1)pg/mL, respectively, P<0.05】 in UCRA-treated groups; the abdominal circumference, ascites depth and urine volume/24 h were (98.6±7.2)cm,(35.2±9.3)mm and (1531.4±234.2)mL, significantly different as compared to [(102.7±6.4)cm, (48.3±11.5)mm and (1249.5±215.1)mL,respectively, P<0.05】 in thesubsided rate in the latter; at the end of six month observation, the ascites synthetical treatment group was 67.3%, significantly higher than 26.9% in the UCRA-treated group (P<0.05). Conclusion The application of alprostadil and terlipressin might assist ultrafiltration, concentration and reinfusion of ascites in treatment of patients with liver cirrhosis and RA, and the long-term efficacy should be observed.

Key words: Liver cirrhosis, Refractory ascites, Alprostadil, Terlipressin, Ultrafiltration, concentration and reinfusion of ascites, Therapy